Total Payments
$829.39
2024 Payments
$14.62
Companies
8
Transactions
75
Medicare Patients
6,450
Medicare Billing
$351,595
Payment Breakdown by Category
Food & Beverage$829.39 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $829.39 | 75 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | $521.53 | 47 | $0 (2020) |
| Allergan Inc. | $135.59 | 17 | $0 (2018) |
| ABBVIE INC. | $86.50 | 5 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $29.44 | 2 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.76 | 1 | $0 (2018) |
| SANOFI-AVENTIS U.S. LLC | $14.90 | 1 | $0 (2022) |
| Vanda Pharmaceuticals Inc. | $14.71 | 1 | $0 (2020) |
| Daiichi Sankyo Inc. | $10.96 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14.62 | 1 | ABBVIE INC. ($14.62) |
| 2023 | $57.88 | 3 | ABBVIE INC. ($57.88) |
| 2022 | $14.90 | 1 | SANOFI-AVENTIS U.S. LLC ($14.90) |
| 2021 | $14.00 | 1 | AbbVie Inc. ($14.00) |
| 2020 | $27.28 | 2 | Vanda Pharmaceuticals Inc. ($14.71) |
| 2019 | $125.47 | 14 | Supernus Pharmaceuticals, Inc. ($114.26) |
| 2018 | $168.71 | 13 | Supernus Pharmaceuticals, Inc. ($123.38) |
| 2017 | $406.53 | 40 | Supernus Pharmaceuticals, Inc. ($271.32) |
All Payment Transactions
75 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/02/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $12.96 | General |
| Category: NEUROSCIENCE | ||||||
| 09/15/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: NEUROSCIENCE | ||||||
| 05/12/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $29.64 | General |
| Category: NEUROSCIENCE | ||||||
| 02/23/2022 | SANOFI-AVENTIS U.S. LLC | SOLIQUA 100/33 (Biological) | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 07/20/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2020 | Supernus Pharmaceuticals, Inc. | OXTELLAR XR (Drug) | Food and Beverage | Cash or cash equivalent | $12.57 | General |
| Category: AED | ||||||
| 02/05/2020 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 12/17/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $12.89 | General |
| Category: AED | ||||||
| 11/19/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.75 | General |
| Category: AED | ||||||
| 09/24/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.13 | General |
| Category: AED | ||||||
| 08/20/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.18 | General |
| Category: AED | ||||||
| 07/22/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $7.88 | General |
| Category: AED | ||||||
| 06/24/2019 | Novartis Pharmaceuticals Corporation | AIMOVIG (Biological) | Food and Beverage | In-kind items and services | $11.21 | General |
| Category: NEUROSCIENCE | ||||||
| 06/18/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.93 | General |
| Category: AED | ||||||
| 05/21/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.16 | General |
| Category: AED | ||||||
| 05/09/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $7.25 | General |
| Category: AED | ||||||
| 04/23/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $7.62 | General |
| Category: AED | ||||||
| 04/13/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $6.13 | General |
| Category: AED | ||||||
| 03/12/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $8.66 | General |
| Category: AED | ||||||
| 02/19/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $4.54 | General |
| Category: AED | ||||||
| 02/09/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $2.14 | General |
| Category: AED | ||||||
| 12/03/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $11.18 | General |
| Category: AED | ||||||
| 11/13/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $17.58 | General |
| Category: AED | ||||||
| 11/13/2018 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $10.95 | General |
| Category: AED | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 1,518 | 2,349 | $270,411 | $98,904 |
| 2022 | 20 | 1,435 | 2,022 | $221,171 | $79,335 |
| 2021 | 26 | 1,730 | 2,734 | $259,340 | $96,967 |
| 2020 | 26 | 1,767 | 2,677 | $225,603 | $76,389 |
Total Patients
6,450
Total Services
9,782
Medicare Billing
$351,595
Procedure Codes
98
All Medicare Procedures & Services
98 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 175 | 175 | $52,325 | $20,864 | 39.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 159 | 223 | $54,066 | $17,223 | 31.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 177 | 279 | $47,830 | $14,199 | 29.7% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 66 | 284 | $40,896 | $13,033 | 31.9% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 25 | 25 | $9,800 | $7,053 | 72.0% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 40 | 171 | $20,799 | $6,096 | 29.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 254 | 445 | $3,773 | $3,608 | 95.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 50 | 50 | $4,550 | $3,597 | 79.0% |
| 91322 | Sarscov2 vac 50 mcg/0.5ml im | Office | 2023 | 14 | 14 | $4,088 | $2,002 | 49.0% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 25 | 48 | $5,376 | $1,717 | 31.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 145 | 193 | $3,860 | $1,469 | 38.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 51 | 51 | $2,952 | $1,457 | 49.4% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 22 | 34 | $3,706 | $1,191 | 32.1% |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | Office | 2023 | 21 | 21 | $1,977 | $747.81 | 37.8% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 26 | 26 | $1,412 | $742.82 | 52.6% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2023 | 41 | 41 | $1,763 | $554.73 | 31.5% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 14 | 14 | $1,162 | $533.12 | 45.9% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 11 | 18 | $1,692 | $526.35 | 31.1% |
| 0124A | Adm sarscv2 bvl 30mcg/.3ml a | Office | 2023 | 11 | 11 | $913.00 | $418.88 | 45.9% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 29 | 30 | $1,590 | $403.20 | 25.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 42 | 47 | $2,115 | $399.79 | 18.9% |
| 73630 | X-ray of foot, minimum of 3 views | Office | 2023 | 16 | 20 | $1,200 | $322.49 | 26.9% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 55 | 75 | $600.00 | $233.25 | 38.9% |
| 72100 | X-ray of lower and sacral spine, 2-3 views | Office | 2023 | 15 | 15 | $990.00 | $232.65 | 23.5% |
| 74019 | X-ray of abdomen, 2 views | Office | 2023 | 13 | 14 | $826.00 | $224.76 | 27.2% |
About Dr. Deborah Haines, DO
Dr. Deborah Haines, DO is a Family Medicine healthcare provider based in Altoona, Iowa. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1679527428.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Deborah Haines, DO has received a total of $829.39 in payments from pharmaceutical and medical device companies, with $14.62 received in 2024. These payments were reported across 75 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($829.39).
As a Medicare-enrolled provider, Haines has provided services to 6,450 Medicare beneficiaries, totaling 9,782 services with total Medicare billing of $351,595. Data is available for 4 years (2020–2023), covering 98 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Altoona, IA
- Active Since 05/19/2006
- Last Updated 03/23/2015
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1679527428
Products in Payments
- TROKENDI XR (Drug) $497.12
- QULIPTA (Drug) $57.88
- VRAYLAR (Drug) $42.95
- LINZESS (Drug) $41.53
- AIMOVIG (Biological) $29.44
- UBRELVY (Drug) $28.62
- VIBERZI (Drug) $25.16
- OXTELLAR XR (Drug) $24.41
- BYSTOLIC (Drug) $19.75
- JARDIANCE (Drug) $15.76
- SOLIQUA 100/33 (Biological) $14.90
- HETLIOZ (Drug) $14.71
- Movantik (Drug) $10.96
- NAMZARIC (Drug) $6.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Altoona
David Lemchak, Do, DO
Family Medicine — Payments: $8,660
Family Medicine $8,660
Mr. Elias Rifkah, Md, MD
Family Medicine — Payments: $8,131
Family Medicine $8,131
Amanda Cattoi-Seifert, Md, MD
Family Medicine — Payments: $6,899
Family Medicine $6,899
Jeffrey Armstrong, Md, MD
Family Medicine — Payments: $2,402
Family Medicine $2,402
Dr. John Reinhardt, D.o, D.O
Family Medicine — Payments: $2,067
Family Medicine $2,067
Sarah Reinhardt, D.o, D.O
Family Medicine — Payments: $1,812
Family Medicine $1,812